Company news

Cynata Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Results of Fully Underwritten Entitlement Offer

October 29, 2026

Results of Fully Underwritten Entitlement Offer

October 29, 2026

September 2026 Quarterly Activity Report & Appendix 4C

October 26, 2026

Prospectus

October 7, 2026

Entitlement Offer & Unmarketable Parcel Sale Facility

October 7, 2026

Termination of At-the-Market Subscription Deed

October 7, 2026

Cynata Receives R&D TI Refund & Repays R&D TI Loan

October 6, 2026

R&D Tax Incentive Loan Facility Extension

September 29, 2026

Notification under Listing Rule 4.3D

September 23, 2026

Appendix 4E & Preliminary Final Report

August 30, 2026

June 2026 Quarterly Activity Report & Appendix 4C

July 29, 2026

Board, Management Changes, Expenditure Reductions, RDTI Loan

July 5, 2026

Reinstatement to Official Quotation

June 18, 2026

CYP-001 GvHD Trial Primary Evaluation Results

June 16, 2026

Suspension from Quotation

June 15, 2026

EU Positive Opinion on CYP-001 Paediatric Investigation Plan

June 2, 2026

Cynata Secures Commitments for $1.5m Placement

May 3, 2026

March 2026 Quarterly Activity Report & Appendix 4C

April 30, 2026

Last Visit in GvHD Trial Completed

March 29, 2026

Appendix 4D & Half-Year Financial Statements

February 26, 2026

December 2025 Quarterly Activity Report and Appendix 4C

January 28, 2026

Cynata Completes $1.2m At-The-Market Raise

January 23, 2026

Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial

December 14, 2025

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

December 14, 2025

Positive DSMB Review in Phase 1/2 Kidney Transplant Trial

December 3, 2025

Final Patient Visit Complete in Phase 3 Osteoarthritis Trial

November 23, 2025

Cynata Receives $1.7m R&D Tax Incentive Refund

November 5, 2025

September 2025 Quarterly Activity Report and Appendix 4C

October 31, 2025

Appendix 4E & Annual Report

August 28, 2025

At-the-Market Subscription Agreement

August 21, 2025

June 2025 Quarterly Activity Report and Appendix 4C

July 30, 2025

CYP-001s FDA Approval Pathway Not Impeded

May 16, 2025

March 2025 Quarterly Activity Report and Appendix 4C

April 24, 2025

Publication comparing Cymerus MSCs to other MSCs

February 4, 2025

Quarterly Activity Report & Appendix 4C

January 29, 2025

First Kidney Transplant Trial Patient Treated

December 11, 2024

Cynata secures commitments for $8.1m institutional placement

December 5, 2024

Demonstrated Safety & Efficacy in DFU Clinical Trial

December 5, 2024

Trading Halt

December 3, 2024

Cynata Receives $1.88m R&D Tax Incentive Refund

November 26, 2024

Study of Cymerus MSCs in Pulmonary Fibrosis Published

August 8, 2024

Cynata to Acquire IP from Tekcyte

July 1, 2024

Further GvHD Clinical Data Published in Nature Medicine

May 22, 2024

DFU Clinical Trial Enrolment Complete

April 7, 2024

EU Approval for Phase 2 CYP-001 Trial in GvHD

March 19, 2024

First Patient Treated in Phase 2 GvHD Trial

March 4, 2024

Encouraging Initial Data from CYP-006TK DFU Trial

February 25, 2024

Recruitment Completed in Phase 3 OA Clinical Trial

December 12, 2023

Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey

December 6, 2023

Cynata Receives $2.315m R&D Tax Incentive Refund

November 13, 2023

Older news releases →

Decks

The 5 newest of 39 decks. Every deck is listed under its year.